Literature DB >> 21402050

sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration.

Gema Martin-Manso1, Maria J Calzada, Yoshiro Chuman, John M Sipes, Charles P Xavier, Vladimir Wolf, Svetlana A Kuznetsova, Jeffrey S Rubin, David D Roberts.   

Abstract

Secreted frizzled-related protein (sFRP)-1 is a Wnt antagonist that inhibits breast carcinoma cell motility, whereas the secreted glycoprotein thrombospondin-1 stimulates adhesion and motility of the same cells. We examined whether thrombospondin-1 and sFRP-1 interact directly or indirectly to modulate cell behavior. Thrombospondin-1 bound sFRP-1 with an apparent K(d)=48nM and the related sFRP-2 with a K(d)=95nM. Thrombospondin-1 did not bind to the more distantly related sFRP-3. The association of thrombospondin-1 and sFRP-1 is primarily mediated by the amino-terminal N-module of thrombospondin-1 and the netrin domain of sFRP-1. sFRP-1 inhibited α3β1 integrin-mediated adhesion of MDA-MB-231 breast carcinoma cells to a surface coated with thrombospondin-1 or recombinant N-module, but not adhesion of the cells on immobilized fibronectin or type I collagen. sFRP-1 also inhibited thrombospondin-1-mediated migration of MDA-MB-231 and MDA-MB-468 breast carcinoma cells. Although sFRP-2 binds similarly to thrombospondin-1, it did not inhibit thrombospondin-1-stimulated adhesion. Thus, sFRP-1 binds to thrombospondin-1 and antagonizes stimulatory effects of thrombospondin-1 on breast carcinoma cell adhesion and motility. These results demonstrate that sFRP-1 can modulate breast cancer cell responses by interacting with thrombospondin-1 in addition to its known effects on Wnt signaling. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402050      PMCID: PMC3085965          DOI: 10.1016/j.abb.2011.03.004

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  90 in total

Review 1.  Secreted WNT antagonists as tumor suppressors: pro and con.

Authors:  Jeffrey S Rubin; Michal Barshishat-Kupper; Farhana Feroze-Merzoug; Zong Fang Xi
Journal:  Front Biosci       Date:  2006-09-01

2.  The structures of the thrombospondin-1 N-terminal domain and its complex with a synthetic pentameric heparin.

Authors:  Kemin Tan; Mark Duquette; Jin-Huan Liu; Rongguang Zhang; Andrzej Joachimiak; Jia-huai Wang; Jack Lawler
Journal:  Structure       Date:  2006-01       Impact factor: 5.006

3.  Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis.

Authors:  J Veeck; D Niederacher; H An; E Klopocki; F Wiesmann; B Betz; O Galm; O Camara; M Dürst; G Kristiansen; C Huszka; R Knüchel; E Dahl
Journal:  Oncogene       Date:  2006-01-30       Impact factor: 9.867

4.  Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.

Authors:  Jeff S Isenberg; Martin J Romeo; Christine Yu; Christine K Yu; Khauh Nghiem; Jude Monsale; Margaret E Rick; David A Wink; William A Frazier; David D Roberts
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

5.  Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.

Authors:  G J Byrne; K E Hayden; G McDowell; H Lang; C C Kirwan; L Tetlow; S Kumar; N J Bundred
Journal:  Int J Oncol       Date:  2007-11       Impact factor: 5.650

Review 6.  The Frizzled family of unconventional G-protein-coupled receptors.

Authors:  Gunnar Schulte; Vítezslav Bryja
Journal:  Trends Pharmacol Sci       Date:  2007-09-19       Impact factor: 14.819

7.  Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma.

Authors:  Michelle L Gumz; Hongzhi Zou; Pamela A Kreinest; April C Childs; Leandra S Belmonte; Shauna N LeGrand; Kevin J Wu; Bruce A Luxon; Mala Sinha; Alexander S Parker; L-Z Sun; David A Ahlquist; Christopher G Wood; John A Copland
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

8.  Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis.

Authors:  Izabela Staniszewska; Shachi Zaveri; Luis Del Valle; Isabela Oliva; Vicki L Rothman; Sidney E Croul; David D Roberts; Deane F Mosher; George P Tuszynski; Cezary Marcinkiewicz
Journal:  Circ Res       Date:  2007-04-05       Impact factor: 17.367

9.  The N-terminal module of thrombospondin-1 interacts with the link domain of TSG-6 and enhances its covalent association with the heavy chains of inter-alpha-trypsin inhibitor.

Authors:  Svetlana A Kuznetsova; Anthony J Day; David J Mahoney; Marilyn S Rugg; Deane F Mosher; David D Roberts
Journal:  J Biol Chem       Date:  2005-07-08       Impact factor: 5.157

10.  Versican-thrombospondin-1 binding in vitro and colocalization in microfibrils induced by inflammation on vascular smooth muscle cells.

Authors:  Svetlana A Kuznetsova; Philip Issa; Elizabeth M Perruccio; Bixi Zeng; John M Sipes; Yvona Ward; Nicholas T Seyfried; Helen L Fielder; Anthony J Day; Thomas N Wight; David D Roberts
Journal:  J Cell Sci       Date:  2006-10-17       Impact factor: 5.285

View more
  16 in total

1.  Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.

Authors:  Katherine L Cook; Anni Wärri; David R Soto-Pantoja; Pamela Ag Clarke; M Idalia Cruz; Alan Zwart; Robert Clarke
Journal:  Clin Cancer Res       Date:  2014-06-15       Impact factor: 12.531

2.  Matricellular proteins in cancer: a focus on secreted Frizzled-related proteins.

Authors:  Krista Marie Vincent; Lynne-Marie Postovit
Journal:  J Cell Commun Signal       Date:  2017-06-07       Impact factor: 5.782

3.  Number and brightness analysis of sFRP4 domains in live cells demonstrates vesicle association signal of the NLD domain and dynamic intracellular responses to Wnt3a.

Authors:  Vanathi Perumal; Kannan Krishnan; Enrico Gratton; Arun M Dharmarajan; Simon A Fox
Journal:  Int J Biochem Cell Biol       Date:  2015-03-21       Impact factor: 5.085

Review 4.  The complex roles of Wnt antagonists in RCC.

Authors:  Sharanjot Saini; Shahana Majid; Rajvir Dahiya
Journal:  Nat Rev Urol       Date:  2011-10-25       Impact factor: 14.432

5.  Secreted Frizzled-related protein potentiation versus inhibition of Wnt3a/β-catenin signaling.

Authors:  Charles P Xavier; Maria Melikova; Yoshiro Chuman; Aykut Üren; Bolormaa Baljinnyam; Jeffrey S Rubin
Journal:  Cell Signal       Date:  2013-09-28       Impact factor: 4.315

Review 6.  Functions of Thrombospondin-1 in the Tumor Microenvironment.

Authors:  Sukhbir Kaur; Steven M Bronson; Dipasmita Pal-Nath; Thomas W Miller; David R Soto-Pantoja; David D Roberts
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 6.208

7.  The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.

Authors:  Heloisa Helena Milioli; Renato Vimieiro; Carlos Riveros; Inna Tishchenko; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

8.  Mice deficient in Sfrp1 exhibit increased adiposity, dysregulated glucose metabolism, and enhanced macrophage infiltration.

Authors:  Kelly J Gauger; Lotfi M Bassa; Elizabeth M Henchey; Josephine Wyman; Brooke Bentley; Melissa Brown; Akihiko Shimono; Sallie S Schneider
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

9.  Comprehensive Analysis of SFRP Family Members Prognostic Value and Immune Infiltration in Gastric Cancer.

Authors:  Dehua Liu; Chenyu Sun; Nahyun Kim; Chandur Bhan; John Pocholo Whitaker Tuason; Yue Chen; Shaodi Ma; Yuting Huang; Ce Cheng; Qin Zhou; Kaiguang Zhang
Journal:  Life (Basel)       Date:  2021-06-03

10.  Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.

Authors:  Christof Bernemann; Carolin Hülsewig; Christian Ruckert; Sarah Schäfer; Lena Blümel; Georg Hempel; Martin Götte; Burkhard Greve; Peter J Barth; Ludwig Kiesel; Cornelia Liedtke
Journal:  Mol Cancer       Date:  2014-07-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.